Targeting mitochondria in hypertrophic cardiomyopathy
- PMID: 36869826
- DOI: 10.1093/eurheartj/ehad081
Targeting mitochondria in hypertrophic cardiomyopathy
Conflict of interest statement
Conflict of interest: C.M. is an advisor to Amgen, Boehringer Ingelheim, Bristol Myers Squibb, NovoNordisk, and Servier, and received speaker honoraria from AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Berlin Chemie, Novartis, and NovoNordisk. The other authors have no conflicts to declare.
Comment on
-
Mitochondrial dysfunction in human hypertrophic cardiomyopathy is linked to cardiomyocyte architecture disruption and corrected by improving NADH-driven mitochondrial respiration.Eur Heart J. 2023 Apr 1;44(13):1170-1185. doi: 10.1093/eurheartj/ehad028. Eur Heart J. 2023. PMID: 36734059 Free PMC article.